Skip Navigation


Rheumatology Advance Access originally published online on April 4, 2007
Rheumatology 2007 46(7):1047-1048; doi:10.1093/rheumatology/kem050
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
46/7/1047    most recent
kem050v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jayne, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jayne, D.
Related Collections
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIALS

Leflunomide versus methotrexate in Wegener's granulomatosis

D. Jayne

Department of Medicine, School of Clinical Medicine, Addenbrooke's Hospital, Box 157, Cambridge CB22QQ, UK

Correspondence to: David Jayne. E-mail: dj106@cam.ac.uk

The first 10% of the full text of this article appears below.

Wegener's granulomatosis has major overlaps with other primary systemic vasculitides, especially microscopic polyangiitis, but also important differences [1]. Its cause is unknown, but it almost always involves the respiratory tract and is more common in cooler latitudes [2]. It typically pursues a protracted relapsing course resulting in chronic morbidity for the patient and an ever widening search for newer, safer therapies by their physician. Combination therapy with cyclophosphamide and corticosteroids, first introduced 35 yrs ago, revolutionized the treatment of Wegener's granulomatosis and converted a frequently fatal disorder into a more chronic relapsing condition [3]. Subsequent clinical investigation has aimed to reduce drug-related toxicity, reduce relapse rates and recover organ function. In particular, the failure of short treatment regimens to induce prolonged disease . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?